Tolvaptan
- TRADE NAME: Samsca (Otsuka)
- INDICATIONS: Chronic heart failure, hyponatremia, polycystic kidneys
- CLASS: Vasopressin receptor antagonist
- HALF-LIFE: 6–8 hours
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Aprepitant, Barbiturates, Benazepril, Captopril, Carbamazepine, Clarithromycin, Conivaptan, Cyclosporine, Darunavir, Delavirdine, Digoxin, Efavirenz, Enalapril, Fosinopril, Grapefruit Juice, Indinavir, Irbesartan, Itraconazole, Ketoconazole, Lapatinib, Lisinopril, Lovastatin, Miconazole, Nefazodone, Nelfinavir, Olmesartan, Oxcarbazepine, P-gp inhibitors, Phenytoin, Quinapril, Ramipril, Rifabutin, Rifampin, Rifapentin, Rifapentine, Ritonavir, Saquinavir, St John's Wort, Strong CYP3A inhibitors, Telithromycin, Voriconazole
PREGNANCY CATEGORY: C
INITIATE AND RE-INITIATE IN A HOSPITAL AND MONITOR SERUM SODIUM
See full prescribing information for complete boxed warning.
Please login to see the rest of this drug profile
SKIN.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
HEMATOLOGIC.
NEUROMUSCULAR/SKELETAL.
OCULAR.
RENAL.
RESPIRATORY.
OTHER.
Page last updated 09/08/2022
Symbol key
Incidence 
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Seriousness
- Hospitalization possible
- Life threatening
- Fatal
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric
